Translational Medicine Division, Brigham and Women's Hospital, Boston, MA 02115, USA.
Semin Hematol. 2010 Jul;47(3):220-6. doi: 10.1053/j.seminhematol.2010.03.005.
Thrombocytopenia is the underlying cause of a number of major clinical conditions and genetic disorders worldwide. While therapeutic agents that bind and stimulate the thrombopoietin receptor are currently available, the development of drugs that directly stimulate megakaryocytes to generate platelets has lagged behind. To improve the management of thrombocytopenia, we will need to define the cell biological pathways that drive the production of platelets from megakaryocytes. This review integrates the latest research of platelet biogenesis and focuses on the molecular pathways that power and regulate proplatelet production.
血小板减少症是全球许多重大临床病症和遗传疾病的根本原因。虽然目前已有结合并刺激血小板生成素受体的治疗药物，但直接刺激巨核细胞生成血小板的药物的研发却一直滞后。为了改善血小板减少症的治疗，我们需要明确驱动巨核细胞生成血小板的细胞生物学途径。本综述整合了血小板生成的最新研究，并重点介绍了驱动和调节伸展出芽的分子途径。
